Expanded Indications Approved for UroLift
FDA has approved new indicationsfor the UroLift System (NeoTract),a treatment for benign prostatichyperplasia that involves placement,via a minimally invasive procedure, ofpermanent implants that relieve prostaticobstruction and open the urethra. UroLift is now approved for use inmen with an obstructive median lobeand men as young as 45 years. Previously,UroLift was contraindicated inpatients with an obstructive medianlobe…